CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.1950
-0.0050 (-2.50%)
Sep 8, 2026, 1:27 PM EST
CytoDyn Balance Sheet
Financials in millions USD. Fiscal year is June - May.
Millions USD. Fiscal year is Jun - May.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Cash & Equivalents | 11.85 | 11.9 | 3.11 | 2.54 | 4.23 |
Cash & Short-Term Investments | 11.85 | 11.9 | 3.11 | 2.54 | 4.23 |
Cash Growth | -0.43% | 282.73% | 22.39% | -39.94% | -87.53% |
Other Receivables | - | 2 | - | - | - |
Receivables | - | 2 | - | - | - |
Prepaid Expenses | 0.75 | 0.25 | 0.46 | 1.17 | 5.2 |
Restricted Cash | - | - | 6.7 | 6.51 | - |
Other Current Assets | 1.28 | 3.72 | 0.54 | 0.59 | 1.09 |
Total Current Assets | 13.88 | 17.88 | 10.82 | 10.81 | 10.52 |
Property, Plant & Equipment | 0.07 | 0.13 | 0.26 | 0.4 | 0.54 |
Other Long-Term Assets | 0.02 | 0.04 | 0.06 | 0.09 | 18.13 |
Total Assets | 13.97 | 18.05 | 11.14 | 11.29 | 29.19 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Accounts Payable | 13.16 | 14.69 | 29.56 | 62.73 | 67.97 |
Accrued Expenses | 14.7 | 20.22 | 17.6 | 17.13 | 14.84 |
Current Portion of Long-Term Debt | 0.86 | 27.2 | 29.79 | 34.42 | 36.24 |
Current Portion of Leases | 0.02 | 0.14 | 0.14 | 0.14 | 0.13 |
Other Current Liabilities | 24.99 | 8.27 | 7.09 | 5.39 | 3.98 |
Total Current Liabilities | 53.73 | 70.52 | 84.18 | 119.8 | 123.16 |
Long-Term Debt | 26.34 | - | - | 0.71 | - |
Long-Term Leases | 0.05 | - | 0.14 | 0.28 | 0.42 |
Other Long-Term Liabilities | 43.57 | 43.57 | 43.57 | - | - |
Total Liabilities | 123.69 | 114.09 | 127.89 | 120.79 | 123.58 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Common Stock | 1.37 | 1.25 | 1.06 | 0.92 | 0.72 |
Additional Paid-In Capital | 819.39 | 790.5 | 773.71 | 731.27 | 671.01 |
Retained Earnings | -930.49 | -887.79 | -891.53 | -841.69 | -766.13 |
Total Common Equity | -109.72 | -96.04 | -116.76 | -109.5 | -94.4 |
Shareholders' Equity | -109.72 | -96.04 | -116.76 | -109.5 | -94.4 |
Total Liabilities & Equity | 13.97 | 18.05 | 11.14 | 11.29 | 29.19 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Total Debt | 27.28 | 27.34 | 30.08 | 35.55 | 36.8 |
Net Cash (Debt) | -15.42 | -15.44 | -26.97 | -33.01 | -32.57 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.01 | -0.01 | -0.03 | -0.04 | -0.05 |
Filing Date Shares Outstanding | 1,382 | 1,251 | 1,214 | 930.52 | 810.28 |
Total Common Shares Outstanding | 1,374 | 1,249 | 1,059 | 918.61 | 719.59 |
Working Capital | -39.85 | -52.64 | -73.37 | -108.99 | -112.65 |
Book Value Per Share | -0.08 | -0.08 | -0.11 | -0.12 | -0.13 |
Tangible Book Value | -109.72 | -96.04 | -116.76 | -109.5 | -94.4 |
Tangible Book Value Per Share | -0.08 | -0.08 | -0.11 | -0.12 | -0.13 |